Gilead's twice-yearly shot to prevent HIV succeeded in a late-stage trial.briefly passed the 5,500 level for the first time on Thursday before pulling back. The broad market index closed down 0.25% while the, meanwhile, rose 299.90 points, or 0.77%, good for its best day this month. Despite turning negative on Thursday, stocks are headed for a winning week, with the S&P 500 and Nasdaq notching new records earlier in the week.
If that trial goes well, the company could bring the shot to market as soon as late 2025. Shares of the company rose about 8.5% and notched their best day since 2022.The Truth Social website on a smartphone arranged in the Brooklyn borough of New York, US, on Friday, Nov. 18, 2022.on Thursday, deepening a sell-off for the stock. The stock saw massive trading volume for the day, as more than 13.2 million shares of Trump Media changed hands — over three times its 30-day average trading volume.
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Jim Cramer's top 10 things to watch in the stock market FridayThe S&P 500 and Nasdaq are taking a breather Friday. But Adobe is surging after a tour-de-force quarter.
Leggi di più »
5 things to know before the stock market opens FridayHere are five key things investors need to know to start the trading day.
Leggi di più »
5 things to know before the stock market opens FridayHere are five key things investors need to know to start the trading day.
Leggi di più »
Jim Cramer's top 10 things to watch in the stock market FridayStocks were lower across the board after a stronger-than-expected May jobs report.
Leggi di più »